What is William Blair’s Estimate for argenx Q1 Earnings?

argenx SE (NASDAQ:ARGX) – Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of argenx in a research note issued on Monday, March 17th. William Blair analyst M. Minter forecasts that the company will post earnings per share of $6.06 for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. William Blair also issued estimates for argenx’s Q2 2026 earnings at $6.23 EPS and Q3 2026 earnings at $7.02 EPS.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%.

Other equities research analysts have also issued research reports about the stock. Robert W. Baird lifted their target price on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research note on Tuesday, March 4th. JMP Securities lifted their target price on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. Truist Financial reissued a “buy” rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Evercore ISI boosted their price objective on shares of argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Sanford C. Bernstein raised shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Monday. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $687.00.

argenx Trading Up 1.4 %

Shares of ARGX opened at $619.97 on Wednesday. The firm’s 50-day moving average price is $636.24 and its 200-day moving average price is $598.37. The firm has a market capitalization of $37.67 billion, a price-to-earnings ratio of -704.51 and a beta of 0.59. argenx has a 1-year low of $349.86 and a 1-year high of $678.21.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in argenx by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company’s stock worth $3,455,207,000 after acquiring an additional 824,750 shares in the last quarter. Janus Henderson Group PLC grew its holdings in argenx by 0.4% during the 3rd quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock worth $1,343,797,000 after acquiring an additional 10,975 shares in the last quarter. Capital World Investors grew its holdings in argenx by 5.1% during the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company’s stock worth $1,099,002,000 after acquiring an additional 86,687 shares in the last quarter. RTW Investments LP grew its holdings in argenx by 2.9% during the 4th quarter. RTW Investments LP now owns 673,497 shares of the company’s stock worth $414,201,000 after acquiring an additional 19,067 shares in the last quarter. Finally, Clearbridge Investments LLC grew its holdings in argenx by 6.8% during the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company’s stock worth $387,344,000 after acquiring an additional 40,330 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.